Biological and clinical developments in melanoma vaccines

Expert Opinion on Biological Therapy

Volumn 1, Issue 3, 2001, Pages 497-510

  Marchand, Marie ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

Author keywords

Cancer; Immunotherapy; Melanoma vaccine; T lymphocyle; Tumour antigen

Indexed keywords

CANCER VACCINE;

CANCER STAGING; HUMAN; MELANOMA; REVIEW;

CANCER VACCINES; HUMAN; MELANOMA; NEOPLASM STAGING;

EID: 0035348163     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.1.3.497     Document Type: Article

References (100)

1. BURNET FM Immunological surveillance in neoplasia. Transplant. Rev. (1971) 7 3-25.
2. MARINCOLA F, JAFFEE EM, HICKLIN DJ, FERRONE S Escape of human solid tumors from T-cell recognition molecular mechanisms and functional significance. Adv. Immunol. (2000) 74 181-273.
3. VAN PEL A, BOON T Protection against a non-immunogenic mouse leukemia by an immunogenic variant obtained by mutagenesLs. Proc. Natl. Acad. Sei. USA (1982) 79 4718-4722.
4. KIRKWOOD JM, IBRAHIM JG, SONDAK VK et al. High and low-dose Interferon alfa-2b in high-risk melanoma first analysis of intergroup trial E1690-S91H/C9190. J Clin. Oncol. (2000) 18 2444-2458.
5. BUZAID AC, BEDIKIAN A, HOUGHTON AN Systemic chemotherapy and biochemotherapy. In Cutaneous Melanoma. Balch CM, Houghton AN, Sober AJ, Soong SJ (Eds.), Quality Medical Publishing, St. Louis, USA (1998) 405-418.
6. LANZAVECCHIA A, SALLUSTOF Dynamics of T lymphocyte responses intermediates, effectors, and memory cells. Science (2000) 290 92-97.
7. INABA K, METLAY JP, CROWLEY MT, STEINMAN RM Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ.J. Exp. Meet. (1990) 172 631-640. The authors demonstrate in a mouse model that DC are professional antigen-presenting cells capable of priming directly naïve T-cells in situ. DC can be considered as 'nature's adjuvant' to the immune response.
8. DUBOIS B, MASSACRIER C, VANBERVLIET B et al.-. Critical role of IH2 in dendritic cell-induced differentiation of naive B lymphocytes, J. Immunol. (1998) 161 2223-2231.
9. FERNANDEZ NC, LOZIER A, FLAMENT C et al. Dendritic cells directly trigger NK cell functions cross-talk relevant in innate anti-tumor immune responses in vivo. Nature Med. (1999) 5 405-411.
10. SCHULER G, STEINMAN RM Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp. Med. (1997) 186 1183-1187.
11. + T helper cells play a crucial role for optimal induction of protective immunity against MHC class II negative tumour cells. This protection is dependent on tumour-specific CTLs. The authors recommend that tumour-specific T helper epitopes should be included in the design of epitope-based vaccines.
12. KIM CJ, PREVETTE T, CORMIER J et al- Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J. Immunotber. (1997) 20 276-286.
13. BUTTERFIELD LH, JILANI SM, CHAKRABORTY NG et al Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol. (1998) 161 5607-5613.
14. CHAUX P, LUITEN R, DEMOTTE N étal.-. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.J. Immunol. (1999) 163 2928-2936. An method to identify CTL epitopes, which selects for naturally processed peptides.
15. RUSSO V, TANZARELLA S, DALERBA P et al. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc. Natl.Acad. Sei. USA (2000) 97 2185-2190.
16. NESTLE FO, ALIJAGIC S, GIIXIET M et al. Vaccination of melanoma patients with pcptidc- or tumor h/satepulsed dendritic cells. Nature Med. (1998) 4 328-332. First report of treatment benefit in a dendritic cell-based clinical trial of patients with melanoma.
17. CHAUX P, VANTOMME V, STROODANT V et al. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp. Med. (1999) 189 767-777.
18. DHODAPKAR MV, STEINMAN RM, SAPP M et al. Rapid generation of broad T-ccll immunity in humans after a single injection of mature dendritic cells. J Clin. Invest. (1999) 104 173-180.
19. YEE C, GILBERT MJ, RIDDELL SR et al. Isolation of tyrosinase-speclfic CDS and CD4 T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol. (1996) 157 4079086.
20. YEE C, SAVAGE PA, LEE PP, DAVIS MM, GREENBERG PD Isolation of high avidity melanoma-reactive CTL from heterogenous populations using peptide-MHC tetramers. J Immunol. (1999) 162 2227-2234.
21. VALMOR! D, PITTET MJ, RIMOLDI D et al An antigentargeted approach to adoptive transfer therapy of cancer. Cancer Res. (1999) 59 2167-2173-
22. AICHELE P, KYBURZ D, OHASHI PS et al. Peptideinduced T-cell tolerance to prevent autoimmune diabetes in a transgcnic mouse model. Proc. Natl. Acacl. Sei. USA (1994) 91 444-448. The protocols of immunisation with a defined MHC class I binding peptide determine whether CTL are induced or tolerised.
23. TOES REM, VAN DER VOORT EIH, SCHOENBERGER SP et al. Enhancement of tumor outgrowth through CTL tolcrization after pcptidc vaccination is avoided by peptide presentation on dendritic cells. J Immunol. (1998) 160 4449456.
24. BERD D, MAGUIRE HC, SCHUCHTER LM et al. Autologous hapten-modificd melanoma vaccine as postsurgical adjuvant treatment after resection 'of nodal métastases. J Clin. Oncol. (1997) 15 2359-2370.
25. BERD D, MAGUIRE HC, KAIRYS JC et al. Post-surgical treatment of clinical stage III melanoma with autologous, hapten-modified vaccine expanded sample size and long-term follow-up. Proc. Am. Soc. Clin. Oncol. (2000) 19 572. Abstract.
26. DUNNION DJ, CYWINSKI AL, TUCKER VC et al. Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumourassociated antigens to cytotoxic T cells in vitro. Immunology (1999) 98 541-550.
27. KUGLER A, STUHLER G, WALDEN P et al. Régression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nature Med. (2000) 6 332-336. A promising approach to cancer immunotherapy.
28. TAMURA Y, PENG P, LIU K, DAOU M, SRIVASTAVA PK Immunotherapy of tumors with autologous tumorderived heat shock protein preparations. Science (1997) 278 117-120.
29. CHANDAWARKAR RY, WAGH MS, SRIVASTAVA PK The dual nature of spécule immunological activity of tumor-derived gp 96 preparations. J Exp. Med. (1999) 189 1437-1442.
30. MORTON DL, FOSHAG LJ, HOON DSB et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. (1992) 216 463-482.
31. HSUEH EC, NATHANSON L, FOSHAG LJ et al.-. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma métastases. Cancer (1999) 85 2160-2169-
32. HSUEH EC, GUPTA RK, QI K, MORTON DL Correlation of specific immune responses with survival in melanoma patients with distant métastases receiving polyvalent melanoma cell vaccine. J Clin. Oncol. (1998) 16 2913-2920.
33. BYSTRYN J Clinical activity of a polyvalent melanoma antigen vaccine. Recent results. Cancer Res. (1995) 139 337-348.
34. WALLACK MK, SIVANANDHAM M, BALCH CM et al Surgical adjuvant active specific immunotherapy for patients with stage in melanoma the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate triaLJ. Am. Coll. Surg. (1998) 187 69-79.
35. HERSEY P, COATES A, MCCARTHY W Vaccinia melanoma cell h/satcs (VMCL) in immunotherapy of stage lib and in melanoma. 3rd International Conference "The adjuvant therapy of malignant melanoma " London, UK (1999).
36. PARDOLL DM, JAFFEE EM Cancer vaccines clinical applications, genetically modified tumor vaccines. In Principles and Practice of the Biologic Therapy of Cancer. Rosenberg SA (Ed.), Lippincott Williams & Wilkins, Philadelphia, USA (2000) 647-662.
37. BOON T, CEROTTINIJ-C, VAN DEN EYNDE B, VAN DER BRUGGEN P, VAN PEL A Tumor antigens recognized by T lymphocytes. Ann. Rev. Imnumol. (1994) 12 337-365.
38. RIVOLTINI L, KAWAKAMI Y, SAKAGUCHI K et al.-. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant pcptide of the human melanoma antigen MART-1. J Immunol. (1995) 154 2257-2265.
39. VAN DER BRUGGEN P, TRAVERSARIC, CHOMEZ P étal. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254 1643-1647. Identification of the first gene coding for a tumour-specific antigen recognised by CTL on a human tumour.
40. TRAVERSARI C, VAN DER BRUGGEN P, LUESCHER IF et ah. A nonapeptidc encoded by human gene MAGE-1 is recognized on HLA-A1 by cytoh/tic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. (1992) 176 1453-1457.
41. COX AL, SKIPPER J, CHEN Y et ah Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell Unes. Science (1994) 264 716-719.
42. BOON T, VAN DEN EYNDE B Cancer vaccines Cancer antigens, shared tumor-specific antigens. In Principles and Practice of the Biologic Therapy of Cancer. Rosenberg SA (Ed.), Lippincott Williams & Wilkins, Philadelphia, USA (2000) 493-504.
43. ROBBINS PF Cancer vaccines Cancer antigens, differentiation antigens. In Principles and Practice of the Biologic Tberapy of Cancer. Rosenberg SA (Ed.), Lippincott Williams and Wilkins, Philadelphia, USA (2000) 504-514.
44. VAN DEN EYNDE B, VAN DER BRUGGEN P T cell-defined tumor antigens. Curr. Opin. Immunol. (1997) 9 684-693-
45. LUCAS S, DE PLAEN E, BOON T MAGE-B5, MAGE-B6, MAGE-C2 and MAGE-C3 four new members of the MAGE family with tumor-specific expression. Int. J. Cancer (2000) 87 55-60.
46. DE SMET C, DE BACKER O, FARAONII et al. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl. Acad. Sei. USA (1996) 93 7149-7153.
47. DE SMET C, LURQUIN C, LETHE B, MARTELANGE V, BOON T DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell. Blol. (1999) 19 7327-7335.
48. DE PLAEN E, ARDEN K, TRAVERSARI C et al. Structure, chromosomal localization and expression of twelve genes of the MAGE family. Immunogenetics (1994) 40 360-369.
49. TANZARELLA S, RUSSO V, LIONELLO I et al. Identification of a promiscuous T cell epitope encoded by multiple members of the MAGE family. Cancer Res. (1999) 59 2668-2674.
50. SCHULTZ ES, LETHE B, CAMB1ASO CL et al. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4 cytotytic T lymphocytes. Cancer Res. (2000) 60 6272-6275.
51. SCHULTZ ES, ZHANG Y, KNOWLES R et al. A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes. Tissue Antigens (2001) 57(2) 103-109.
52. LU1TEN RM, DEMOTTE N, TINE J, VAN DER BRUGGEN P A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules. Tissue Antigens (2000) 56 77-81.
53. TÜRECI 0, SAHIN U, SCHOBERT I et ah. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res. (1996) 56 4766-i772.
54. CHEN Y-T, SCANLAN MJ, SAHIN U et ah. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Nail. Acad. Sei. USA (1997) 94 1914-1918.
55. TÜRECI Ö, SAHIN U, ZWICK C et ah. Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc. Nail. Acad. Sei. USA (1998) 95 5211-5216.
56. AARNOUDSE CA, VAN DEN DOEL PB, HEEMSKERK B, SCHRIER PI Intcrleukin-2-induced, melanoma-specific T cells recognize camel, an unexpected translation product of LAGE-1. Int.J. Cancer (1999) 82 442-448.
57. MARTELANGE V, DE SMET C, DE PLAEN E, LURQUIN C, BOON T Identification on a human sarcoma of two new genes with tumor-specific expression. Cancer Res. (2000) 60 3848-3855.
58. GUILLOUX Y, LUCAS S, BRICHARD VG et ah. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosamlnyltransfcrase V gene. J. Exp. Meet. (1996) 183 1173-1183-
59. LUPETTI R, PISARRA P, VERRECCHIA A et al. Translation of a retained intron in tyrosinase-related protein (TRP)-2 mRNA generates a new cytotoxic T lymphocyte (CTL)-dcfined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. J Exp. Med. (1998) 188 1005-1016.
60. BRICHARD V, VANPELA, WOLFELTe/aJ. Thetyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HIA-A2 melanomas. J Exp. Med. (1993) 178 489-495.
61. WÖLFEL T, VAN PEL A, BRICHARD V et al Two tyrosinase nonapeptides recognized on H1A-A2 melanomas by autologous cytorytic T lymphocytes. Eur.J. Immunol. (1994) 24 759-764.
62. MOREL S, OOMS A, VAN PEL A et al. A tyrosinase peptide presented by H1A-B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes. Int. J Cancer (1999) 83 755-759.
63. BRICHARD VG, HERMANJ, VAN PEL A etal Atyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur.J. Immunol. (1996) 26 224-230.
64. TOPALIAN SL, GONZALES MI, PARKHURST M et al Melanoma-specific CD4+T cells recognize nonmutated HIA-DR-restricted tyrosinase epitopes. J Exp. Med. (1996) 183 1965-1971.
65. + T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. Cancer Res. (1998) 58 296-301.
66. COULIE PG, BRICHARD V, VAN PEL A et al A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp. Med. (1994) 180 35-42.
67. KAWAKAMI Y, ELIYAHU S, SAKAGUCHI K et al Identification of the immunodomlnant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-rcstricted tumor infiltrating himphocytes. J. Exp. Med. (1994) 180 347-352.
68. ZAROUR HM, KIRKWOOD JM, SALVUCCI KIERSTEAD L et al Melan-A/MART-lsi-73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4 T cells. Froc. Natl. Acad. Sei. USA (2000)97 400-405.
69. VISSEREN MJW, VAN ELSAS A, VAN DER VOORT EIH et al CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lysc melanoma cells. J Immunol (1995) 154 3991-3998.
70. PITTET MJ, VALMORI D, DUNBAR PR et al High frequencies of naive Melan-A/MART-1-specific CDS T cells in a large proportion of human histocompatibility leukocyte antigen (HLA>A2 individuals. J Exp. Med. (1999) 190 705-715.
71. LUDEWIG B, OCHSENBEIN AF, ODERMATT B et al. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J. Exp. Med. (2000) 191 795-803. The results obtained in a transgenic mouse model reveal the delicate balance between tumour immunity and autoimmunity and point out important limitations for the use of not strictly tumour-specific antigens in antirumour vaccination with DC.
72. IJVINGSTON PO, WONG GYC, ADLURIS et al. Improved survival in stage III melanoma patients with GM2 antibodies a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. (1994) 12 1036-1044.
73. KIRKWOOD JM, IBRAHIM J, SONDAK VK, SOSMAN JA, EMSLOFF MS Relapse-free and overall survival are significantly prolonged by high-dose IFN alpha 2b (HDI) compared to vaccine GM2-KLH with QS21 (GMK, Progenies) for high-risk resected stage IIB-III melanoma results of the intergroup phase III study. Ann. Oncol. (2000) 11 50. Abstract.
74. SAHIN U, TURECI O, SCHMITT H et al. Human neoplasms elicit multiple spécule immune responses in the autologous host. Proc. Natl. Acad. Set. USA (1995) 92 11810-11813. Using serum antibodies of cancer patients, the authors developed a new fast method to identify genes coding for tumour antigens. Provided the genes have a tumour-specific pattern of expression, the encoded epitopes subsequently identified represent good potential targets for antitumour vaccination.
75. JÄGER E, CHEN Y-T, DRIJFHOUT JW et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1 definition of human hlstocompatibility leukocyte antigen (HLA>A2-binding peptide epitopes. J Exp. Med. (1998) 187 265-270.
76. MARCHAND M, VAN BAREN N, WEYNANTS P et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HIA-A1. Int.J. CancerWm) 80 219-230.
77. WEBER JS, HUA FL, SPEARS L et al. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J. Immitnother. (1999) 22 431-440.
78. JÄGER E, BERNHARD H, ROMERO P et al Generation of cytotoxic T-cell responses with synthetic melanomaassociated peptides in vivo implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer (1996) 66 162-169.
79. JÄGER E, RINGHOFFER M, DIENES HP et al. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int.J. Cancer(l996) 67 54-62.
80. SALGALLER ML, MARINCOLA FM, CORMIER JN, ROSENBERG SA Immunization against epitopes in the human melanoma antigen gplOO following patient immunization with synthetic peptides. Cancer Res. (1996) 56 4749-1757.
81. CORMIER JN, SALGALLER ML, PREVETTE T et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan-A. Cancer J. Set. Am. (1997) 3 37-44.
82. ROSENBERG SA, YANG JC, SCHWARTZENTRUBER DJ et al. Immunologie and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with mctastatic melanoma. Nature Med. (1998) 4 321-327. Objective tumour responses were obtained in 13/31 patients with metastatic melanoma treated with a gplOO synthetic peptide designed to increase binding to HLA-A2 molecules, associated with high doses IL-2. There was no correlation between clinical and immune responses to vaccination.
83. ROSENBERG SA, YANG JC, SCHWARTZENTRUBER DJ et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J. Immunol. (1999) 163 1690-1695-
84. WANG F, BADE E, KUNIYOSHI C et ah Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res. (1999) 5 2756-2765.
85. SCHEIBENEGGEN C, SCHMITTEL A, KEILHOLZ U et al Phase 2 trial of vaccination with tyroslnasc peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunotber. (2000) 23 275-281.
86. LEWIS JJ, JANETZKI S, SCHAED S et al. Evaluation of CDS T-cell frequencies by the élis pot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int. J. Cancer (2000) 87 391-398.
87. KRUIT WH, VAN BAREN N, HUMBLET Y et al. Phase I/H study of vaccination with MAGE-3 protein plus immunological adjuvant SB AS-2 in HLA Class I selected patients with MAGE-3 positive tumors. Proc. Amer. Soc. Clin. Oncol. (2000) 19 479a, Abstract.
88. ROSENBERG SA, ZHAI Y, YANG JC et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gplOO melanoma antigens. J. Natl. Cancer. Inst. (1998) 90 1894-1900.
89. TOURNER B, HAENDLE I, RODER C et ah Vaccination with MAGE-3A1 peptide-pulsed mature, monocytederived dendritic cells expands specific cytotoxic T cells and induces regression of some métastases in advanced stage IV melanoma. J. Exp. Med. (1999) 190 1669-1678.
90. MACKENSEN A, HERBST B, CHEN J-L et ah Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34 hcmatopoietic progenitor cells. Int.J. C Hcer(2000) 86 385-392.
91. MUKHERJI B, CHAKRABORTY NG, YAMASAKI S et ah Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sei. USA (1995) 92 8078-8082.
92. HU X, CHAKRABORTY NG, SPORN JR et al. Enhancement of cytolytic T lymphocyte precursor frequency In melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Kes. (1996) 56 2479-2483.
93. YEE C, THOMPSON JA, ROCHE P et al. Melanocytedestruction after antigen-specific immunotherapy of melanoma direct evidence of T-cell mediated vitiligo. J. Exp. Med. (2000) 192 1637-1643. This study provides direct evidence in humans that antigenspecific immunotherapy can generate autoimmune toxicity when tumour antigens shared with normal tissues are used.
94. Z1TVOGEL L, REGNAULT A, LOZIER A et al Eradication of established murine tumors using a novel cell-free vaccine dendritic cell-derived exosomes. Nature Med. (1998) 4 594-600.
95. FALLARINO F, UYTTENHOVE C, BOON T, GAJEWSKI TF Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptidcpulsed peripheral blood mononuclcar cells by coadministration of recombinant murine interleukin-12. Int.J. Cancer (1999) 80 324-333.
96. GAJEWSKI TF, FALLARINO F, ASHIKARI A, SHERMAN M Immunization of HLA-A2+ melanoma patients with MAGE-3 or MclanA pcptldc-pulscd autologous pcriph. eral blood mononuclear cells plus recombinant human interleukin 12. Clin. Cancer Res. (2001) 7(3) 895s-901s.
97. ALTAIAN JD, MOSS PAH, GOULDER PJR etal. Phenotypic analysis of antigen-specific T lymphocytes. Science (1996) 274 94-96. Powerful new technology to study antigen-specific T-cells.
98. DUNBAR PR, OGG GS, CHEN J et al. Direct isolation, phenotyping and cloning of low-frequency antigenspecific cytotoxlc T lymphocytes from peripheral blood. Curr. Biol. (1998) 8 413-416.
99. ROMERO P, ROD DUNBAR P, VALMORI D et al Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tctramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. (1998) 188 1641-1650.
100. LEE PP, YEE C, SAVAGE PA et al Characterization of circulating T cells specific for tumor-associated antigens In melanoma patients. Nature Med. (1999) 5 677-685.